Natural Brand B-12 vitab12.com
Natural Brand B-12 vitab12.com
Canada Drug ID #01983423
Natural Brand B-12 vitab12.com

"It's Just That Simple"
Low B12 intake can lead to blood and metabolic problems, particularly in lactating mothers or diabetics: pernicious anemia, neurological disorders, problems in fat metabolism and red blood cell synthesis.
Many vegetarians may not be getting adequate amounts of cyanocobalamin B12.


 Natural Therapy
ORDER SUBLINGUAL B12



American ExpressDiscover CardVisaMastercard
Kosher Organic Buckwheat Mattresses and Pillows
Natural Kosher Organic Buckwheat Mattresses and Pillows

Oral Cobalamin for Pernicious Anemia


Medicine's Best Kept Secret?

Department of Medicine From the Department of Medicine, Minneapolis Veterans Affairs Medical Center, University of Minnesota. Presented at the annual meeting of the Society of General Internal Medicine, Washington, DC, May 2, 1990. THE TREATMENT of pernicious anemia with cobalamin is one of medicine's great success stories. However, the usual practice of giving the drug as an intramuscular injection has several drawbacks. Injections can be painful, difficult to provide for some patients who are elderly or living alone, (1) and costly if given by health professionals. (2) It is therefore not surprising that the search for an oral preparation began soon after cobalamin was isolated and introduced for parenteral use in 1948. Preparation containing oral intrinsic factor were tried, but antibody production caused some patients to become refractory and relapse. (3) Other studies revealed that a small but constant proportion of an oral dose of cyanocobalamin was absorbed without intrinsic factor, so that by sufficiently increasing the dose, adequate absorption could be attained. (4,5)
Promising results from early studies of oral cyanocobalamin therapy led to the use of increasingly larger doses, and several groups reported complete success with doses of 300 to 1000 ug. (6,8) The largest study described 64 Swedish patients with pernicious anemia and other cobalamin deficiency states who were treated with 1000 ug of oral cyanocobalamin daily, with 61 of these patients treated for more than 3 years,. Clinical and hematologic remissions, normalization of serum levels, and full replenishment of hepatic stores were observed in all patients. (8,9)
Oral therapy is currently used by 40% of patients requiring cobalamin replacement in Sweden (R. Berlin, MD, written communication, November 1989), where it has proved to be a completely safe alternative to B-12 injections. (10) In the United States, oral therapy ceased to be available in the late 1950s. Much to the regret of all hematologists and patients who had used the tablets. (1) Oral therapy became available again in this country in the early 1970's, but it is rarely prescribed. In a survey of 245 Minneapolis (Minn.) internists, none had used oral cobalamin to treat pernicious anemia, and only 1% had used it to treat dietary cobalamin deficiency.
The texts, despite their concerns, advocate a larger role for oral cobalamin therapy than that employed by the surveyed internists. How valid are the concerns expressed by the texts? The concerns regarding unpredictable absorption grew out of the occasional low serum cobalamin levels reported in early studies using 100 to 250 ug of oral cyanocobalamin daily. These reports led the US Pharmacopeia Anti-Anemia Preparations Advisory Board to caution against oral therapy for pernicious anemia as being at best, unpredictably effective. (15) The observed responses to these doses can now be considered predictable in light of more recent absorption data. The mean absorption rate of oral cyanocobalamin by patients with pernicious anemia is 1.2% across a wide range of doses. (8) The daily cobalamin turnover rate is about 2 ug/d, so an oral dose of 100 to 250 ug/d is sufficient for most patients.
Due to individual variation of absorption, (4) however, some patients have borderline serum levels when taking doses as high as 500 ug daily. In a study of 64 patients taking 500 ug daily, the lowest absorption rate was 1.8 ug/d, slightly less than the turnover rate. (8) A dose of 1000 ug daily is therefore preferable, as confirmed by the previously cited log-term treatment studies. (8) Although the Swedish investigators successfully used 1000 ug daily for initial therapy, they have recommended that 2000 ug twice daily or injections be used for the first month to rapidly replenish body stores. (8) The use of doses that are excessive for most patients is acceptable because cobalamin is inexpensive, as will be discussed, and without known toxic effects even when given in large quantities.
The texts also express concern regarding compliance with oral cobalamin therapy, though it is clear why cobalamin is singled out from other oral therapies (e.g., thyroid replacement) in this regard. Studies of oral cobalamin therapy noted good compliance,
in some cases better than with injections. (5,8) If closer monitoring is deemed necessary, physicians and patients might still prefer oral therapy and more frequent measurement of serum cobalamin levels to monthly injections.
Finally, although high cost was cited as a disadvantage of oral cobalamin in one text as recently as 1983,(12) this has not been true since the early 1950s. A year's supply of generic 1000 ug cyanocobalamin tablets costs the pharmacist about $10. Parenteral cobalamin is also inexpensive, but the charge for administering it by health professionals can be considerable. (2) Typical charges for a single injection are $10 to $20 in aclinic and $60 to $100 for a visiting home nurse. More than one third of patients receiving cobalamin injections from the Minneapolis Veterans Affairs Medical Center receive their injections from visiting or clinic nurses, suggesting that increased use of oral cobalamin would result in substantial savings.
Despite the success of parenteral cobalamin for the treatment of pernicious anemia, it is clear from the Swedish experience and survey results discussed herein that a wider appreciation of the effectiveness and availability of oral cobalamin therapy would be valuable to American physicians and their patients. It is time to let the secret out.
Frank A. Lederle, MD- Article in JAMA, January 2, 1991 - Vol 265, No.1, pg 94-95.
  1. Crosby WH. Improvisation revisited: oral cyanocobalamin without intrinsic factor for pernicious anemia. Arch Intern Med. 1980;140:1582.
  2. Middleton J, Wells W. Vitamin B-12 injections: considerable source of work for the district nurse. BMJ. 1985;290:1254-1255.
  3. Lowenstein L., Cooper BA, Brunton L, Gartha S, Kerner K. An immunological basis for acquired resistance to oral administration of hog intrinsic factor and vitamin B-12 in pernicious anemia. J Clin Invest. 1961;40:1656-1662.
  4. Doscherholmen A, Hagen PS, Liu M, Olin L. A dual mechanism of vitamin B-12 plasma absorption. J Clin Invest. 1957; 36:1551-1557.
  5. Reisner EH, Weiner L, Schittone MT, Henck EA. Oral treatment of pernicious anemia with vitamin B-12 without intrinsic factor. N England Journal of Medicine. 1955;253:502-506.
  6. McIntrye PA, Hahn R, Masters JM, Krevans JR. Treatment of pernicious anemia with orally administered cyanocobalamin (vitamin B-12). Arch Intern Med. 1960;106:280-292.
  7. Waife SO, Jansen CJ, Crabtree RE, Grinnan EL, Fouts PJ. Oral vitamin B-12 without intrinsic factor in the treatment of pernicious anemia. Ann Intern Med. 1963; 58:810-817.
  8. Berlin H, Berlin R, Brante G. Oral treatment of pernicious anemia with high doses of vitamin B-12 without intrinsic factor. Acta Med Scand. 1968;184:247-258.
  9. Berlin R, Berlin H, Brante G, Pilbrant A. Vitamin B-12 body stores during oral and parenteral treatment of pernicious anemia. Acta Med Scand. 1978; 204:81-84.
  10. Berlin R,. Vitamin B-12 injections. BMJ. 1985;291:56.
  11. Crosby WH. Overtreating the deficiency anemias. Arch Intern Med. 1986; 146:779.
  12. Babior BM, Bunn HF. Megaloblastic anemias. In: Petersdorf RG, Adams RD, Braunwald E, Isselbacher KJ, Martin JB, Wilson JD, eds. Harrison's Principles of Medicine. 10th ed. New York, NY: McGraw-Hill International Book Co; 1983:1859.
  13. Wintrobe MN, Lee GR, Boggs DR, et al. Clinical Hematology. 8th ed. Philadelphia, PA: Lea & Febiger; 1981:592,
  14. Beck WS. Megaloblastic anemias. In: Wyngaarden JB, Smith LH, eds. Cecil Textbook of Medicine. 18th ed, Philadelphia, PA: WB Saunders Co; 1988:905.
  15. Bethell FH, Castle WB, Conley CL, London IM. Present status of treatment of pernicious anemia: ninth announcement of USP Anti-Anemia Preparations Advisory Board. JAMA. 1959;171:2092-2094.

Sublinqual (under tongue) Vitamin B-12
B12 Vitamin Cyanocobalimin
"MORE THAN ANEMIA PROTECTION!"

 Natural Therapy
SHOPPING CART



American ExpressDiscover CardVisaMastercard


Los Angeles Tel: 949-528-3809
Canada Tel: 604-520-0727
Leave Call Back-Number and Comment:

Super Learning superlearning.com
SUPER FAST LEARNING SYSTEM

[More Than Anemia] [B12 General Monograph] [Oral B-12] [Pernicious Anemia] [The Trouble with B12] [B12 Info] [M.S. & B12] [Cyanocobalimin] [You & B12] [Folic Acid Info]
[Home]



© vitab12.com Since 1997 - All Rights Reserved
1.0 Shadow Marketing Group, Ltd.
Updated:

The products and the claims made about specific products on or through this site have not been evaluated by Vitab12.com or the United States Food and Drug Aministration and are not approved to diagnose, treat, cure or prevent disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem.